

## Valneva announces successful outcome of its AGM and renewal of the term of office of its management board members

**Lyon (France), June 26, 2015** – Valneva SE (“Valneva”), a leading pure-play vaccines biotech company announced today that all the resolutions supported by the management board (excluding one resolution which lacked quorum) have been adopted by the shareholders at its Annual General Meeting (AGM) held in Paris on June 25, 2015.

The resolutions included the approval of the 2014 financial statements, limited delegations for the management board to increase the share capital or to issue financial instruments, and an update of Valneva’s articles of association.

The detailed voting results of the AGM will be available in the “Investors & Media” section of the Company’s corporate website at the beginning of next week.

The company also announced that the term of office of its management board members - Thomas Lingelbach, President and CEO, Franck Grimaud, Deputy CEO and Reinhard Kandra, Chief Financial Officer – which were due to expire in June 2016 has been renewed by Valneva’s supervisory board for a period of 3 years, i.e. until June 2019.

### **About Valneva SE**

Formed in 2013 through the merger of Intercell AG and Vivalis SA, Valneva is a biotechnology company developing, manufacturing and commercializing innovative vaccines with a vision to protect people from infectious diseases.

The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

Valneva’s portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese encephalitis (IXIARO<sup>®</sup>) and the second (Dukoral<sup>®</sup>) indicated for the prevention of cholera and, in some countries, ETEC infection or traveler’s diarrhea caused by ETEC (*Enterotoxigenic Escherichia coli*). The company has proprietary vaccines in development including candidates against *Pseudomonas aeruginosa*, *Clostridium difficile* and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66<sup>®</sup> vaccine production cell line, IC31<sup>®</sup> adjuvant).

Valneva is headquartered in Lyon, France, listed on Euronext-Paris and the Vienna stock exchange and operates out of France, Austria, Scotland and Sweden with approximately 400 employees. More information is available at [www.valneva.com](http://www.valneva.com).



Contact:

Laetitia Bachelot-Fontaine  
Head of Investor Relations  
& Corporate Communications  
T +02-28-07-14-19  
M +33 (0)6 4516 7099  
[Communications@valneva.com](mailto:Communications@valneva.com)

Teresa Pinzolits  
Corporate Communications Specialist  
T +43-1-206 20-1116  
M +43-676-84 55 67 357